Raup-Konsavage Wesley M, Carkaci-Salli Nurgul, Greenland Kelly, Gearhart Robert, Vrana Kent E
Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Keystone State Testing, LLC, Harrisburg, Pennsylvania, USA.
Med Cannabis Cannabinoids. 2020 Sep 17;3(2):95-102. doi: 10.1159/000510256. eCollection 2020 Dec.
Several studies have found that cannabinoids, particularly delta-9-tetrahydrocannabinol and cannabidiol (CBD), have the ability to reduce cancer cell viability. An ongoing debate regarding the use of medical Cannabis revolves around the effectiveness of pure compounds versus intact plant material for treatment. Proponents for the use of intact plant material or botanical extracts argue that there is a synergistic effect between the different cannabinoids, terpenoids, and flavonoids; this is commonly referred to as the "entourage effect." Our study was designed to test the validity of the proposed entourage effect in a narrow application using a cancer cell viability model.
Six cancer cell lines, from 3 different types of human cancer were treated with 10 μM pure CBD or 10 μM CBD from hemp () oil (obtained from 3 different commercial sources) for 48 h, and cell viability was measured with the MTS assay. Dose-response curves were then performed to compare the potencies of pure CBD to CBD oils. CBD concentrations were independently confirmed in the commercial oils, and cannabinoid and terpene composition were also compared.
CBD (10 μM) was able to reduce cell viability in 3 of the 6 cell lines tested, and this was found to be cell line specific and not specific to select cancers. None of the CBD oils tested were able to reduce viability to a greater extent than that of pure CBD. Additionally, dose-response curves found lower IC values for pure CBD compared to the most potent CBD oil tested. Interestingly, some oils actually appeared to protect cancer cells from the effects of CBD.
We found that pure CBD was as potent or more potent at reducing cancer cell viability as the most potent oil tested, suggesting that there is no "entourage" effect under these specific in vitro conditions.
多项研究发现，大麻素，尤其是Δ⁹-四氢大麻酚和大麻二酚（CBD），具有降低癌细胞活力的能力。关于医用大麻使用的持续争论围绕着纯化合物与完整植物材料在治疗方面的有效性展开。支持使用完整植物材料或植物提取物的人认为，不同的大麻素、萜类化合物和黄酮类化合物之间存在协同效应；这通常被称为“随从效应”。我们的研究旨在使用癌细胞活力模型在一个狭窄的应用中测试所提出的随从效应的有效性。
用10 μM纯CBD或10 μM来自大麻（）油（从3个不同商业来源获得）的CBD处理来自3种不同类型人类癌症的6种癌细胞系48小时，并用MTS法测量细胞活力。然后进行剂量反应曲线以比较纯CBD与CBD油的效力。对商业油中的CBD浓度进行独立确认，并比较大麻素和萜烯组成。
CBD（10 μM）能够降低所测试的6种癌细胞系中的3种的细胞活力，并且发现这是细胞系特异性的，而非特定于某些癌症。所测试的CBD油均不能比纯CBD更大程度地降低活力。此外，剂量反应曲线发现，与所测试的最有效的CBD油相比，纯CBD的IC值更低。有趣的是，一些油实际上似乎能保护癌细胞免受CBD的影响。
我们发现，纯CBD在降低癌细胞活力方面与所测试的最有效的油一样有效或更有效，这表明在这些特定的体外条件下不存在“随从”效应。
